Sansure Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	-	4,590	4,233	3,213	2,636
Trading Asset Securities	-	139.67	548.28	2,451	2,046
Cash & Short-Term Investments	4,005	4,730	4,782	5,664	4,683
Cash Growth	-15.32%	-1.09%	-15.57%	20.95%	11.70%
Accounts Receivable	-	560.69	692.26	1,298	807.66
Other Receivables	-	27.58	23.49	82.41	14.3
Receivables	-	588.27	715.75	1,381	821.95
Inventory	-	392.75	376.63	355.31	369.5
Other Current Assets	-	78.7	75.45	125.83	92.09
Total Current Assets	-	5,790	5,950	7,525	5,966
Property, Plant & Equipment	-	1,113	1,043	785.27	481.03
Long-Term Investments	-	1,096	974.33	657.43	513.23
Goodwill	-	7.66	7.66	-	-
Other Intangible Assets	-	334.67	283.28	79.12	45.55
Long-Term Deferred Tax Assets	-	69.28	73.82	69.62	25
Long-Term Deferred Charges	-	147.27	97.05	46.7	16.26
Other Long-Term Assets	-	47.04	25.16	10.19	43.08
Total Assets	-	8,604	8,454	9,174	7,090
Accounts Payable	-	225.78	271.14	586.26	188.82
Accrued Expenses	-	290.03	363.33	622.39	231.82
Short-Term Debt	-	9	9	-	-
Current Portion of Leases	-	5.28	11.1	14.26	8.49
Current Income Taxes Payable	-	0.21	17.66	145.25	80.16
Current Unearned Revenue	-	64.55	32.81	53.11	78.64
Other Current Liabilities	-	159.94	214.12	150.45	76.01
Total Current Liabilities	-	754.8	919.15	1,572	663.93
Long-Term Debt	-	396.65	-	-	-
Long-Term Leases	-	11.92	18.21	13.6	6.41
Long-Term Unearned Revenue	-	39.88	32.49	30.53	25.68
Long-Term Deferred Tax Liabilities	-	54.75	59.45	19.04	13.01
Other Long-Term Liabilities	-	-	-	26.09	-
Total Liabilities	-	1,258	1,029	1,661	709.03
Common Stock	-	582.39	588.46	588.46	400
Additional Paid-In Capital	-	1,702	1,908	1,914	2,065
Retained Earnings	-	5,194	5,177	5,371	4,082
Treasury Stock	-	-274.29	-515.33	-392.6	-200.01
Comprehensive Income & Other	-	39.01	43.26	19.36	21.71
Total Common Equity	7,131	7,243	7,201	7,501	6,369
Minority Interest	-	102.56	223.64	12.16	12.43
Shareholders' Equity	7,220	7,346	7,425	7,513	6,381
Total Liabilities & Equity	-	8,604	8,454	9,174	7,090
Total Debt	1,103	422.85	38.31	27.86	14.9
Net Cash (Debt)	2,902	4,307	4,743	5,636	4,668
Net Cash Growth	-32.61%	-9.20%	-15.83%	20.74%	12.83%
Net Cash Per Share	4.98	7.35	8.09	9.63	7.93
Filing Date Shares Outstanding	591.88	573.72	573.52	578.69	592
Total Common Shares Outstanding	574.18	573.72	572.21	578.69	592
Working Capital	-	5,035	5,030	5,954	5,302
Book Value Per Share	12.42	12.62	12.59	12.96	10.76
Tangible Book Value	5,845	6,901	6,910	7,421	6,323
Tangible Book Value Per Share	10.18	12.03	12.08	12.82	10.68
Buildings	-	834.41	826.53	344.51	231.04
Machinery	-	607.96	436.62	322.65	270.13
Construction In Progress	-	3.58	4.59	267.76	110.45

Source: S&P Global Market Intelligence. Standard template. Financial Sources.